Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cancer cachexia is a complex metabolic process affecting up to 80% of patients suffering from an advanced-stage cancer. Moreover, 20 to 40% of all cancer deaths are caused directly by cachexia. Recently, omega-3 fatty acids have gained interest for their beneficial effects in cancer cachexia. Moreover, nutritional supplementation enriched with omega-3 could potentially maintain body weight in cancer patients undergoing intensive treatment.

The investigators aims in this study is to evaluate the effect of omega-3 supplementation on body composition, functional capacity, inflammatory profile and quality of life in cervix cancer patients undergoing chemoradiotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients

NCT03720158

Head and Neck Squamous Cell Carcinoma Quality of Life Radiotherapy; Complications

TERMINATED NA

Omega-3 Hydrogel and Prevention of Oral Mucositis

NCT05214495

Mucositis Oral

COMPLETED PHASE2/PHASE3

Effect of an Oral Supplement on the Total Energy and Protein Intake of Head and Neck Cancer Patients in the Last 2 Weeks of Radiation Therapy

NCT00375700

Head and Neck Cancer

WITHDRAWN NA

A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients

NCT02948699

Malignant Neoplasm of Nasopharynx

UNKNOWN PHASE4

Individualization of Nutritive Sensory Support Of Radiation Therapy

NCT05046028

Radiotherapy; Complications Head and Neck Cancer

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omega-3

Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.

Group Type EXPERIMENTAL

Omega-3

Intervention Type DIETARY_SUPPLEMENT

patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.

Olive oil

Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.

Group Type PLACEBO_COMPARATOR

Olive oil

Intervention Type DIETARY_SUPPLEMENT

patients included in this group will take 4 capsules per day of olive oil.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3

patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.

Intervention Type DIETARY_SUPPLEMENT

Olive oil

patients included in this group will take 4 capsules per day of olive oil.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

intervention group placebo group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cervix cancer at FIGO stage II and III
* Chemoradiotherapy treatment proposal (cisplatin + radiotherapy)
* Nutritional diagnosis of pre-cachexia ou cachexia